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AChR monoclonal antibody isolated 
from a myasthenia gravis patient
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We report here the sequence and functional characterization of a recombinantly expressed 
autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of 
thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high 
degree of somatic mutations as well as a 6 amino acid insertion within the VHCDR2. The recombinant 
mAb 131 is specific for the γ-subunit of the fetal AChR to which it bound with sub-nanomolar apparent 
affinity, and detected the presence of fetal AChR on a number of rhabdomyosarcoma cell lines. Mab 
131 blocked one of the two α-bungarotoxin binding sites on the fetal AChR, and partially blocked the 
binding of an antibody (mAb 637) to the α-subunit of the AChR, suggesting that both antibodies bind at 
or near one ACh binding site at the α/γ subunit interface. However, mAb 131 did not reduce fetal AChR 
ion channel currents in electrophysiological experiments. These results indicate that mAb 131, although 
generated from an MG patient, is unlikely to be pathogenic and may make it a potentially useful reagent 
for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita which can 
be caused by fetal-specific AChR-blocking autoantibodies.
Myasthenia gravis (MG) with antibodies against the acetylcholine receptor (AChR) is an autoimmune disease 
of the neuromuscular junction (NMJ)1–3. The anti-AChR-autoantibodies cause loss of AChRs from the postsyn-
aptic muscle membrane of the NMJ, resulting in failure of neuromuscular transmission and muscle weakness. 
The AChR is a ligand-gated ion channel and exists in fetal and adult forms each comprising four homologous 
subunits. Two α1, one β1 and one δ-subunit are expressed in combination with either the γ (“fetal” form, pre-
dominantly in developing muscle fibers) or the ε-subunit (“adult” form, at the NMJ in innervated muscle fibers). 
The AChR opens upon binding of acetylcholine (ACh) molecules to sites located on the α/ε (or α/γ) and α/δ 
interfaces. Antibodies against both the fetal (α2βγδ) and the adult (α2βεδ) AChR are found in MG patients, many 
binding to the shared α-subunits, but some patients have additional antibodies specific for the fetal γ-subunit, or 
more rarely the adult ε-subunit4–7.
AChR autoantibodies are predominantly IgG1 with some IgG3, and little IgG4. They lead to a decrease of 
AChR numbers and/or loss of function by three mechanisms8: antigenic modulation, in which antibodies diva-
lently cross-link adjacent receptors leading to internalization and degradation of antibody/antigen complexes; 
complement-dependent damage caused by IgG1 and IgG3 subclass antibodies9,10; and less commonly functional 
inhibition of the ACh binding site so that the AChR channel does not open in response to released ACh8. During 
human development, the fetal AChR is expressed at the NMJ, and only replaced by the adult form from about 30 
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weeks gestation. In rare cases fetal-specific antibodies in a mother (with or without adult AChR antibodies and 
clinical MG) cross the placenta and inhibit the function of the fetal AChR leading to arthrogryposis multiplex 
congenita (AMC), a condition resulting from lack of fetal movement. AMC comprises multiple joint contractures, 
lung hypoplasia and profound respiratory impairment with the risk of fetal death or neonatal mortality7,11–14.
The fetal AChR (α2βγδ) is also expressed in human rhabdomyosarcoma (RMS) cells, which is the most com-
mon type of soft tissue malignancy in children15. Most patients with RMS respond well to available standard 
treatments including chemotherapy and irradiation, with 5-year survival rates of >70%16. In an experimental 
model, RMS cells proved sensitive to treatment with an immunotoxin-labeled human anti-γ-AChR scFv antibody 
fragment; possibly this finding opens a new approach for efficient, highly specific treatment17.
Monoclonal/recombinant (auto)antibodies against the AChR are essential tools for the study of MG, AMC 
and RMS. One suitable source for cloning AChR antibodies are the B cells derived from the thymus removed 
from patients with MG18–21.
In a previous study using the thymus of an early-onset MG patient, we generated a monoclonal B-cell line 
against the γ-subunit of the fetal AChR (clone P90-131)20. The monoclonal antibody (IgG1 isotype, mAb 131) did 
not cross-react with AChRs of mouse, rat or rhesus monkey muscle which are of the adult type and also did not 
bind to AChR from Torpedo electric organ which is of the gamma type (independent of development). In view of 
the possible application in RMS, we characterized the cloned anti-γ-AChR antibody in more detail. We used the 
B-cell receptor DNA sequence of clone P90-131 to produce the corresponding recombinant IgG1-131 and IgG4-
131 antibodies, in order to determine their properties in relation to AChR-MG, AMC and RMS.
Results
Analysis of the mAb 131 sequence. The complete sequences of the VH and Vκ chains of mAb 131 anno-
tated with the complementarity-determining regions (CDR)s are shown in Fig. 1. The replacement to silent (R/S) 
mutation ratio, amino acid changes and mutational hotspot analysis of V gene segments of mAb 131 are summa-
rized in Tables 1 and 2 respectively. The VH gene segment of mAb 131 differentiated from the V3-30*03 (L26401) 
and IGHJ5*02 germline genes as suggested by 55.7% and 82.9% homology, respectively. The sequence encoding 
the CDR 1, 2 and the framework regions (FR) of the VH gene had a high replacement to silent (R/S) mutation 
ratio. There were a large number of mutations in the RGYW and WRCY hotspot region of the VH including an 
Figure 1. Sequence of the 131 VH and Vκ genes. IgG1-131 VH and Vκ nucleotide/amino acid sequences (red) 
were analyzed using IMGT/V-QUEST program and aligned with the closest germline alleles (black). A hyphen 
represents nucleotide identity with the germline sequence. VH and Vκ CDRs are marked within arrowed lines.
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18 bp (6 AA) insertion in the CDR2. The Vκ and Jκ sequence shared 89.1% and 92.9% homology to V1-9*01 
(K02096) and IGKJ4*01 alleles, respectively, with multiple mutations observed in VκCDR1 and VκCDR3 while 
the VκCDR2 used the conserved sequence from V1-9*01. Comparing the IgV gene of mAb 131 to the IgV genes 
of previously described anti-AChR antibodies7,20,22–25, no V gene was preferentially/ dominantly used between 
the different antibodies.
Production and validation of recombinant human IgG1 and IgG4 isotypes of mAb 131. For 
recombinant expression of mAb 131, the V regions of heavy and light chains were synthesized de novo and 
cloned into plasmids for the transient expression of IgG1 and IgG4 isotypes in HEK293 cells (see Fig. 2a and b 
for schematic representations of the constructs for VH-CH and Vκ-Cκ, respectively). The successful secretion 
of the antibodies into the medium was verified by dot-blot with anti-human IgG, IgG1 and 4 isotype-specific 
HRP-conjugated secondary antibodies (Fig. 2c).
IgG1-131 binds the γ-subunit of fetal AChR with high specificity and affinity. IgG1-131 specif-
ically recognized the recombinant γ-subunit of the AChR in Western blots (Fig. 3a) of recombinant α, β and 
γ extracellular domains of the AChR (produced in yeast). The γ-subunit specificity was confirmed by ELISA, 
where IgG1-131 bound to recombinantly expressed γ-subunit, but not to the α or β subunit (Fig. 3b). By radio-
immunoprecipitation using cell extracts containing the complete AChR radiolabeled with 125I-α-bungarotoxin 
(125I-α-BT), IgG1-131 precipitated the fetal AChR, but not the adult AChR (Fig. 3c). More than half of the fetal 
AChR in the assay could be precipitated by 1 nM IgG1-131, suggesting a subnanomolar apparent affinity of the 
antibody. The recombinant antibody IgG1-131 did not show any cross-reactivity with AChR derived from extracts 
of rat and mouse denervated muscles or Torpedo californica electric organ (Fig. 3d), as previously demonstrated 
with the original P90-131 B-cell line20. In a radioimmunoprecipitation assay, mAb 131 binding to the γ-subunit 
partially prevented binding of α-BT to the fetal AChR: the 125I-α-BT bound to fetal AChR in the presence of 
IgG1-131 (10 nM) was approximately 60% less when compared to a control mAb IgG1-637 that is specific for the 
α-subunit of the AChR (p < 0.001, Fig. 3e).
The results in Fig. 3e were consistent with the notion that IgG1-131 displaced 125I-α-BT from one of its two 
binding sites, similar to that seen with AMC serum which displaced ~50% of 125I-α-BT from the fetal AChR26. 
To investigate this we used a clinical diagnostic assay to test displacement of 125I-α-BT from the AChR. In line 
with the findings by Riemersma et al.26, we found that serum from a patient with a history of 4 pregnancies 
affected by AMC blocked ~50% of 125I-α-BT binding to the AChR. IgG1-131 blocked 125I-α-BT binding to a 
similar degree (Fig. 3f). As expected, the negative control and IgG1-637 did not block 125I-α-BT binding to the 
AChR. Accordingly, there was a significant difference between IgG1-131 and the negative control (p < 0.001), 
and also between IgG1-131 and IgG1-637 (p < 0.001). Since bungarotoxin binds to the α-subunit, while IgG1-
131 binds to the γ-subunit, the results also suggested that IgG1-131 binds near the α/γ subunit interface. To see 
whether this was the case, we performed a competition experiment with IgG1-131 and IgG1-637 in a radioim-
munoprecipitation assay: In comparison to IgG1-637 alone, adding an excess of IgG1-131 significantly decreased 
125I-α-BT-binding to the precipitated AChR (Fig. 3g). Using IgG1-131 alone decreased 125I-α-BT-binding to the 
AChR even further, suggesting that the binding epitopes of both antibodies are too close for simultaneous binding 
near the α/γ subunit interface, and that only IgG1-131 has a 125I-α-BT blocking effect (schematically shown in 
Fig. 3h).
Anti-AChR monoclonal antibodies target RMS cell lines. Since the fetal AChR is a diagnostic marker 
of RMS27, we were interested to see whether IgG1-131 binding to the 5 well-characterized RMS lines could be 
detected by immunofluorescence. These included the embryonal lines TE671 and RD, and the alveolar lines 
VH VHFR1 VHCDR1 VHFR2 VHCDR2 VHFR3 VHCDR3*
R/S nt 91/9 8/0 17/0 33/2 11/0 22/7 0/0
AA Change/Identical 48/30 5/0 7/1 15/2 7/1 14/24 0/2
Vκ VκFR1 VκCDR1 VκFR2 VκCDR2 VκFR3 VκCDR3
R/S nt 16/13 0/1 4/2 7/3 1/0 0/5 4/2
AA Change/Identical 13/74 0/18 4/2 5/12 1/2 0/36 3/4
Table 1. Analysis of R/S ratio and amino acid changes in V gene segments of mAb 131. *IMGT/V-QUEST V 
gene analysis excludes DH and JH regions.
FR1 CDR1 FR2 CDR2 FR3 CDR3
VH rgwy 2 1 3 1 1 0
VH wrcy 3 1 1 0 5 0
Vκ rgwy 1 2 3 0 3 2
Vκ wrcy 1 0 5 1 4 2
Table 2. Analysis of rgwy and wrcy mutational hotspots in V gene segments of mAb 131. Source - IMGT/V-
QUEST programm (http://www.imgt.org/IMGT_vquest/share/textes/).
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RH30, RH41 and CRL2061. As a control for AChR expression, mAb 637 was used in parallel. Immunoreactivity 
to TE671, RD, RH41 and CRL2061 cells was observed for both AChR antibodies; in contrast, no immunofluores-
cence was detected in RH30 cells stained by either antibody (Fig. 4a). Moreover, we cultured cells with or without 
these antibodies and subsequently measured the remaining 125I-α-BT binding sites on the cell surface. Binding 
of 125I-α-BT to TE671, RD, RH41 and CRL2061 was observed (Fig. 4b), while binding to RH30 cells was very 
low. Both AChR antibodies (at a concentration of 10 nM) significantly reduced 125I-α-BT binding to TE671, RD, 
RH41 and CRL2061 cells (p < 0.001), while in RH30, no effect was observed. The low 125I-α-BT and IgG binding 
to RH30 cells suggests lower AChR expression as compared to the other cell lines17.
IgG1-131 does not modulate cell surface AChR. Many AChR antibodies have been shown to cause 
modulation of cell surface AChRs which is dependent on cross-linking between molecules. Antigenic modu-
lation was initially measured by quantifying the release of 125I following the degradation of 125I-α-BT-labelled 
AChRs28,29. As explained above for RMS cell lines, we used an alternative method23,24,30,31 in which we first incu-
bated the cells with antibody and subsequently with 125I-α-BT, to measure the bound 125I-α-BT on the surface 
of the cells. The degradation of AChR can be conveniently detected by reduction of 125I-α-BT binding sites, but 
can be confounded by antibodies that directly block 125I-α-BT binding to AChRs32. Concentrations of ≥1 nM 
IgG1-637 or IgG4-637 (unmodified mAb/ not Fab-arm exchanged) both reduced α-BT binding well below 20% 
of the levels on the cell surface of untreated TE671 and CN21 cells (Fig. 5a/5b) within 3 h  at 37 °C, in line with 
the strong antigenic modulation capacity of this antibody33. However, at a concentration of 0.1 nM or higher, 
IgG1-131 and IgG4-131 both caused ~50% reduction in binding of 125I-α-BT to the TE671 RMS cell (Fig. 5c/5d), 
in agreement with its ability to block one of the two α-BT binding sites. IgG1-131 had no effect on α-BT binding 
to the adult AChR (expressed on the CN21 cells), confirming its γ-subunit specificity. Already after 1 h of incu-
bation, both IgG1-131 and IgG1-637 (at 10 nM) reduced α-BT binding to the surface of TE671 by 50% (Fig. 5e). 
The reduction by IgG1-131 is thought to derive from displacement of one of the two 125I-α-BT from the AChR. 
During the following 2 hours, α-BT binding continued to decrease significantly in IgG1-637-treated cells. In 
contrast, during this time period, α-BT binding remained stable in IgG1-131-treated cells, suggesting that it did 
not induce antigenic modulation.
To further study a potential modulation effect of mAb 131, we generated a monovalent IgG4 version of the 
antibody by Fab arm-exchange (FAE), as described33,34. During FAE, mono-specific IgG4 antibodies randomly 
exchange “half-molecules” (consisting of a heavy chain – light chain pair) giving rise to bispecific IgG4 molecules 
(Fig. 5f) that lose the ability to cross-link the same antigen and can be considered as functionally monovalent. To 
set up an in vitro FAE reaction, IgG4 was purified from normal human serum and validated by a dot blot assay 
along with IgG1-637 and IgG4-637 (Fig. 5g). As expected, the modulatory effect of control antibody IgG1-637 
Figure 2. Overview of IgG1-131 & IgG4-131 cloning strategy and production. The expression cassettes for 
the production of (a) VH-CH and (b) Vκ-Cκ segments of the mAb 131 in IgG format are shown. (c) Isotype 
specificities of the recombinant antibodies along with control mAbs were analyzed by dot blot using isotype 
specific HRP-conjugated antibodies.
www.nature.com/scientificreports/
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Figure 3. Recombinant IgG1-131 binds fetal AChR and γ-subunit with high specificity and apparent affinity. 
(a) The α, β and γ-subunits of the human muscle AChR were resolved on SDS-PAGE (shown in upper panel) 
and specificity of IgG1-131 for γ-subunit was analyzed by Western blot (lower panel). Full image of the SDS-
PAGE and Western blot are shown in Supplementary Fig. S1. (b) ELISA analysis of IgG1-131 (0.01 nM – 10 
nM) binding to the α, β and γ-subunit of the AChR. (c) Radio-immunoprecipitation of IgG1-131 using 
fetal and adult AChR extracted from TE671 and CN21 cell membranes respectively. (d) Cross-reactivity of 
IgG1-131 against rat and mouse muscle AChR, and the Torpedo electric organ AChR was analyzed by radio-
immunoprecipitation assay. (e) The specificities of IgG1-131 and IgG4-131 were tested against fetal (TE671 
membrane extract) and adult AChR (CN21 membrane extract). IgG1-637 and IgG4-637 were used as a 
reference in both tests. (f) 125I-α-BT blocking was measured as percentage inhibition in the 125I-α-BT binding 
to AChRs after co-incubating the individual antibody/AMC serum and 125I-α-BT labelled AChR. The results 
are from two independent experiments. (g) Analysis of competition between IgG1-131 and IgG1-637. IgG1-131 
(100 nM) when co-incubated with IgG1-637 (25 nM), reduced the amount of 125I-α-BT co-precipitated with 
fetal AChR compared to 25 nM IgG1-637 alone. (h) Schematic representation of the binding effects of mAb 131 
and mAb 637. The mAb 637 binds to the two designated α-subunits of the fetal AChR, allowing simultaneous 
binding of two α-BT molecules. However, in the presence of competing/blocking mAb 131, one of the α-BT 
molecules and mAb 637 at the α/γ interface gets displaced by mAb 131.
www.nature.com/scientificreports/
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(which does not block 125I-α-BT binding) was completely neutralized by a 99 fold excess of FAE IgG4-637 anti-
body (p < 0.001, Fig. 5h). Similar to IgG1-131, Fab-arm exchanged IgG4-131 strongly reduced 125I-α-BT binding 
to TE671 cells (Fig. 5h). A 99-fold molar excess of Fab-arm exchanged IgG4-131 antibody did not significantly 
Figure 4. IgG1-131 binds to human RMS cell lines. (a) Binding of IgG1-131 and IgG1-637 to cell surface fetal 
AChR on different RMS cell lines was analyzed by immunofluorescence. Binding of antibody was detected by 
goat anti-human IgG-Alexa 488 antibody (green) and Hoechst was used to stain the nuclei. HEK293 cells were 
used as negative control for each antibody. Representative images at 20x magnification are shown, n = 2. Scale 
bar = 50 µm. (b) Analysis of 125I-α-BT bound to cell surface AChR on RMS cell lines after incubation with IgG1-
131 or IgG1 637. Individual bars correspond to the mean ± SD of three replicates tested for each condition. 
Results are representative of 3 independent experiments.
www.nature.com/scientificreports/
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Figure 5. IgG1-131 does not lead to modulation of fetal AChR on TE671 cells, but partly displaces 125I-α-BT. 
The effect of (a) IgG1-637, (b) IgG4-637, (c) IgG1-131 and (d) IgG4-131 on the 125I-α-BT binding to TE671 
(fetal AChR) and CN21 (adult AChR) cells is shown as normalized cell bound radioactivity at varying molar 
concentrations of the antibodies. Cells were incubated with antibodies for 3 h and subsequently labelled 
with 125I-α-BT. Each data point corresponds to the mean ± SD of three replicates. (e) Effect of IgG1-131 and 
IgG1-637 on 125I-α-BT binding to TE671 cells at different time points (1, 2 and 3 h). For each time point, cells 
cultured in medium without any IgG were used as controls. Unspecific binding of 125I-α-BT was measured by 
pre-incubation of cells with an excess of unlabeled α-BT (25 nM). Data points of 1, 2 and 3 hours incubation 
were pooled for this condition. (f) Schematic representation of the Fab arm-exchange reaction under reducing 
conditions between IgG4-131 (VH and VL domains shown in red and CH in black color) and IgG4 from 
normal human serum (IgG4-NHS; VH and VL domains shown in blue and CH in grey color) to yield two 
bispecific IgG4 molecules. (g) Purity of IgG4 isolated from normal human serum (NHS) was validated by dot 
blot assay along with control mAbs. (h) Competition experiments using monovalent FAE IgG4-131 and IgG4-
637. The loss of the cell bound radioactivity due to the IgG1-131 incubation was not significantly affected by 
an excess FAE IgG4-131. In contrast, FAE IgG4-637 completely counteracted the effect of IgG1-637. Data are 
pooled from 3 experiments with representative groups.
www.nature.com/scientificreports/
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counteract the reduction of 125I-α-BT binding sites on TE671 cells caused by 1 nM IgG1-131. This suggests that 
the antigenic modulation capacity of IgG1-131 is absent or very low and that instead it mainly reduced 125I-α-BT 
binding to the fetal AChR.
IgG1-131 does not inhibit fetal AChR currents in transfected HEK293 cells. As IgG1-131 partially 
blocked binding of α-BT, which is well known to compete with ACh and other agonists or competitive antago-
nists for the ACh binding site, we asked whether IgG1-131 itself inhibited AChR function. To this end, whole-cell 
currents were measured in transfected HEK293 cells expressing fetal AChR in the presence or absence of IgG1-
131. ACh applications of 1 s duration were performed to elicit AChR currents. All recordings were started with 
control solutions lacking IgG1-131 (“control solution”) followed by the “test solution” containing 33 nM IgG1-
131. Compared to control solution there was no current reduction during a 2.5 min application of the test solution 
(peak current amplitude of −5.4 ± 1.2 nA and −5.1 ± 1.1 nA, respectively; p = 0.87; Fig. 6a). Even continuous 
perfusion with IgG1-131 containing test solution for more than 20 min did not result in any significant current 
reduction (Fig. 6b), suggesting that mAb131 did not block AChR function.
Discussion
The fetal AChR is expressed mainly during development and has relevance for human disease. In a rare form of 
AMC, fetal-specific inhibitory antibodies from the mother cause fetal paralysis and often fetal death during gesta-
tion. In RMS, the fetal AChR is expressed on the cell surface and may provide a target for specific immunotoxins. 
In this study the patient-derived recombinant IgG1-131, cloned by B cell immortalization from the thymus of an 
MG patient, was shown to bind to the fetal AChR with high apparent affinity, to prevent binding of α-BT to one 
of its two sites on the fetal AChR, but not to cause internalization or inhibit the ion channel-function of the fetal 
AChR.
Since mAb 131 was isolated by B cell immortalization, this specificity is associated with the original heavy and 
light chain partners. The antibody V genes had accumulated a large number of overt mutations in the CDRs. The 
high replacement to silent (R/S) mutation ratio among V genes indicated that the somatic hypermutation of the 
antibody was driven by its antigen35,36.
Our results also showed that mAb 131 has only a weak capacity for antigen modulation and merely displaces 
one of the 125I-α-BT molecules. Apparently, in our previous study20, we had incorrectly interpreted the loss of cell 
bound α-BT induced by mAb 131 as due to antigen modulation.
IgG1-131 bound specifically to the γ-subunit of the fetal AChR, but partially competed with α-subunit-specific 
IgG1-637. Since IgG1-131 did not affect the ACh-induced receptor currents, the results suggest that the antibody 
binding site is located on the α/γ interface and overlaps with the α-BT binding site, but not with the binding site 
for ACh. Previous reports showed that the sera of healthy mothers with obstetric history of AMC7,26 and sera 
of 5 out of 12 parous women with MG7 contained antibodies that inhibited α-BT binding to the fetal AChR by 
~50% and also blocked the fetal AChR response to ACh in electrophysiological and22Na flux studies. However, 
the administration of α-BT blocking anti-AChR antibodies purified from MG serum has also been reported to 
protect mice from in vivo toxicity of α-BT without inducing any of the clinical MG symptoms in the animals37. 
In another study, the α-BT blocking antibody titers correlated less with the changes in muscle weakness when 
compared to the binding antibody titers38. These observations suggest additional antigenic epitopes on the fetal 
specific gamma subunit, and at the alpha/gamma interface; antibodies binding to these epitopes do not have 
pathogenic effects but could protect against pathogenic antibodies.
Since α-BT has a size of ~8000 Da, in comparison with 162 Da for ACh, it is perhaps not surprising that anti-
bodies, when binding to various subunits of the AChR, more commonly block α-BT rather than ACh binding 
and that these two blocking effects do not always coincide. So far, monoclonal antibodies generated using thymic 
B cells from MG patients7,22,24, including some that are specific for the fetal AChR have not been reported to 
Figure 6. IgG1-131 does not inhibit fetal AChR function. (a) AChR currents (mean ± SEM) in individual cells 
(n = 6) were measured during the continuous perfusion with control solution (without IgG1-131) and with test 
solution (application of 5 μg/mL purified IgG1-131 for 2.5 min). (b) Repetitive AChR current measurements in 
an individual cell continuously perfused with 10 mL of test solution. Data points are the means ( ± SEM) of a 
number of measurements (control solution: n = 10, test solution: n = 6 at 0.5 min, n = 6 at 8 min, n = 6 at 15 min 
and n = 3 at 22 min). AChR currents were normalized to the cell capacitance and expressed as pA/pF.
www.nature.com/scientificreports/
9ScIeNtIfIc RepoRTS | 7: 14426  | DOI:10.1038/s41598-017-14350-8
interfere with AChR function, but the example of mAb 131 and several other antibodies7 confirms that the fetal 
AChR is a major target of B cells in the thymus of EOMG patients.
While it is clear that mAb 131 is not pathogenic by antigenic modulation, it could, being of the IgG1 isotype, 
still damage the fotus by activation of complement. It is known that the early gestation stage (12 weeks) is marked 
by the maturation of the neuromuscular junction in the masseters (and presumably other muscles) of the human 
fetus39 and, therefore, overactivation of the complement system, associated with normal pregnancies40–42 might 
potentially contribute to a pathogenic effect of mAb 131. In other antibody-mediated diseases, such as antiphos-
pholipid syndrome (APS) and systemic lupus erythematosus (SLE), the complement system is involved in transfer 
of the disease from mother to child: a pathogenic effect of APS antibodies due to complement activation has been 
shown in a mouse model and in human placental tissue of SLE and APS subjects43.
A ‘non-pathogenic’ role of mAb 131 could be of interest for RMS diagnosis and therapy15,17, because this can-
cer type expresses high amounts of AChRs of the fetal type. Indeed, mAb 131 was found to bind specifically, in 
the nanomolar range, to various human RMS cell lines of embryonal and alveolar origin as seen with immunoflu-
orescent staining. This suggests that mAb 131 could be of diagnostic or clinical relevance and encourages further 
development for use of this antibody to target RMS.
Methods
Sequence analysis. The variable heavy and light chain genes of mAb 131 were PCR amplified with VH/JH 
and Vκ/Jκ primer and sequenced20. The sequences were analyzed by comparison with human germline alleles 
using the IMGT/V-QUEST program (http://www.imgt.org/IMGT_vquest/share/textes/).
Cloning and expression of fully human IgG1-131 and IgG4-131. The VH and Vκ expression cas-
settes were designed by the incorporation of the restriction sites (5′EcoRI/3′NheI for VH and 5′AgeI/3′BsiWI for 
Vκ respectively) compatible with the pFUSE expression system (Invivogen/Life Technologies), Kozak transla-
tion initiation sequence, and a signal peptide from pIgG1-63733; both constructs were chemically synthesized by 
GeneArt. The VH and Vκ genes were sub-cloned respectively into the pFUSE-CHIg-hG1, pFUSE-CHIg-hG4 and 
pFUSE-CLIg-hκ vectors (Fig. 2a/b). HEK293 cells were cultured in DMEM (Gibco, Cat No. 10938-025) supple-
mented with 50 U/mL penicillin, 50 U/mL streptomycin & 1% L-glutamine and co-transfected with heavy and 
light chain plasmids (1 μg:1.5 μg/106 cells) using 1:3 ratio of DNA and linear polyethylenimine (PEI, Polyscience 
Inc, Cat No. 23966). An equivalent amount of medium with 10% FCS was added to the cultures 4 h after the trans-
fection. The cells were cultured for 5 to 7 days. To verify successful expression, the secreted IgG in the supernatant 
was concentrated by Amicon Ultra-15 centrifugal filter units (MWCO of 100 kDa, Millipore, Cat No. UFC910024) 
and measured with a sandwich ELISA using goat F(ab’)2 anti-human IgG-Fcγ (Jackson Immuno-Research, Cat 
No. 109-006-008; diluted 1:200) for coating, and bound IgG was detected with HRP-conjugated goat F(ab’)2 
anti-human IgG-Fcγ (Jackson Immuno-Research, Cat No. 109-036-008; diluted 1:20,000). The concentration of 
the expressed antibody was calculated relative to the human serum IgG standards as μg/mL.
IgG was purified from 50 mL culture supernatant using a HiTrap Protein G HP column (GE Healthcare Life 
Science, Cat No. 17-0404-01) in an AKTA explorer 900 system (GE Healthcare Life Science), eluted with 0.2 M 
sodium citrate pH 3.0, and concentrated using a Centricon Plus-20 centrifugal filter device (MWCO of 30 kDa, 
Millipore, Cat No. UFC2 LTK 08). Purified mAbs IgG1-131, IgG4-131, as well as mAbs IgG1-637 & IgG4-637 as 
controls, were blotted on nitrocellulose membranes (Biorad, Cat No. 162-0116) for 1 h at 37 °C, blocked with 5% 
non-fat dry milk in 1x PBS for 1 h at 37 °C, washed with PBS-T (containing 0.05% Tween20) and incubated with 
HRP-conjugated goat F(ab’)2 anti-human IgG-Fcγ (Jackson Immuno-Research, Cat No. 109-036-008; diluted 
1:2500) or mouse anti-human IgG1 (Invitrogen, Cat No. 05-3320; diluted 1:2500) or mouse anti-human IgG4 
(AbD serotec, Cat No. MCA2098P; diluted 1:2500) secondary antibody. The blots were developed with 20% DAB 
in sodium acetate citric acid buffer pH 5.5 activated by 5 μL 30% H2O2.
Analysis of antibody binding to AChRs. The binding of antibodies to cell membrane extracts contain-
ing the fetal AChR (expressed on the TE671 rhabdomyosarcoma cells) and the adult AChR (expressed on the 
CN21 cells) was detected in a standard radio-immunoprecipitation assay. 10 nM each of IgG1-131 and IgG1-637 
were incubated overnight at 4 °C with respective cell extracts (~3 fM of human AChR) labelled with an excess 
of 125I-α-BT (3.4 TBq/mM, Perkin Elmer, Cat No. NEX126) and normal human serum as a co-precipitant/car-
rier. The immune-complexes were precipitated by adding 150 μL of goat serum with anti-human IgG at 4 °C 
and gamma counts were recorded after 4 h. Results were expressed as normalized values or as co-precipitated 
125I-α-BT binding sites per liter of sample in nmol/L.
IgG1-131 and α-BT competition was also tested using ARAb blocking RIA following the manufacturer’s 
instructions (IBL International, Cat No. RE21033). The assay is based on competitive binding of anti-AChR anti-
bodies in a sample and 125I-α-BT to the AChR. Results were expressed as percentage inhibition of 125I-α-BT 
binding to AChRs.
The binding of IgG1-131 to AChR in membrane extracts from rat denervated muscle (100 μL), mouse den-
ervated muscle (50 μL) and Torpedo electric organ (0.05 μg) was determined by radio-immunoprecipitation as 
described above. Normal human and rat sera were included as negative controls while EAMG (experimental 
autoimmune myasthenia gravis) rat serum was included as a positive control for murine and Torpedo AChR 
detection.
The specificity of IgG1-131 was further determined by Western blot analysis using 5 μg recombinantly 
expressed extracellular domains (ECD) of the human AChR subunits from the yeast Pichia pastoris44, that were 
resolved on 10% SDS-PAGE under reducing condition and transferred to a PVDF membrane (Millipore, Cat No. 
IPFL00010). The blotted subunits were blocked with 1:2 dilution of OdysseyTM blocking buffer (LI-COR, Cat No. 
P/N 927-40100), incubated with 1:100 dilution of IgG1-131 for 1 h and then incubated with IRDye 800CW goat 
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anti-human IgG (H + L) (LI-COR, Cat No. 926-32232) for 1 h at a dilution of 1:5000. The membrane was scanned 
using the Odyssey CLx imaging system. Additionally, the affinity of IgG1-131 against the fetal AChR and recom-
binant subunits of human muscle AChR was determined at varying antibody concentrations (0.01 nM - 10 nM) 
by radio-immunoprecipitation assay and an indirect antigen ELISA, respectively23.
AChR staining on RMS cell lines. RMS cell lines were cultured on poly-D-lysine-coated (1%) glass cov-
erslips (12 mm diameter, n = 6) in a six well tissue culture plate up to 75% confluence. Thereafter, medium was 
removed; cells were washed once with PBS, fixed using 3% paraformaldehyde solution for 5 min, washed once 
with PBS and blocked with 5% goat serum for 30 min. The coverslips were then removed from the culture plate 
and incubated upside-down on a 50 μL drop of PBS with 3 μg/mL of IgG1-131, IgG1-637, normal human serum 
IgG or 1% BSA along with 2 μg/mL Hoechst stain (Sigma Aldrich, Cat No. B2261) for 1 h. The coverslips were 
washed sequentially three times by dipping in 1x PBS followed by incubation on 50 μL drops of 1:1000 diluted 
goat anti-human IgG-Alexa 488 antibody (Molecular Probes/Invitrogen, Cat No. A11013). Coverslips were 
mounted on gelatin coated glass slides using 10 μL of 80% glycerol in PBS and analyzed at 20x magnification on 
an Olympus BX51 fluorescence microscope.
In vitro cell surface 125I-α-BT binding and AChR antigenic modulation assay. RMS cell lines of 
alveolar origin (RH30, RH41 & CRL2061) were cultured in RPMI 1640 (Gibco, Cat No. 12633-012) with 10% FCS 
and embryonal RMS cell lines (TE 671,CN21 & RD) were maintained in DMEM (Gibco, Cat No. 10938-025) sup-
plemented with 10% FCS. Other supplements included 50 U/mL penicillin and streptomycin, 1% L-glutamine, 
1% sodium pyruvate and 0.1% dexamethasone. The cells were seeded into a 48 well tissue culture plate and grown 
to confluence for 4 days. The confluent cultures were incubated with different molar concentrations (0.001 nM–10 
nM) of test and control mAbs diluted in an incubation medium (DMEM supplemented with 40 μM cyclohex-
imide) for 1–3 h at 37 °C/5% CO2. Cells were washed once with 1x PBS and further incubated with the labeling 
medium (100 μL DMEM containing 1:5000 125I-α-BT) for 1 h at 37 °C/5% CO2. The cells were washed three times 
with 1x PBS and then lysed by 0.5 N NaOH for 10 min before measuring 125I gamma counts. The non-specific 
binding of 125I-α-BT to the cells was measured as gamma counts in samples that had been pre-incubated with 
25 nM unlabeled α-BT. The residual cell bound radioactivity (125I-α-BT) was normalized to the 125I-α-BT CPM 
of the cells incubated with the corresponding culture medium only.
In vitro Fab arm-exchange and cell surface fetal AChR protection. IgG4 from 1:2 diluted normal 
human serum was purified by AKTA explorer 900 through a CaptureSelect human IgG4 affinity matrix (Life 
Technologies, Cat No. 290005) and analyzed by dot blot as described in “Cloning and expression of full IgGs” 
section (Fig. 5g). In vitro FAE was induced by co-incubating 10 μg/mL IgG4-131 or IgG4-637 with 500 μg/mL 
IgG4 (1:50) purified from normal human serum with 0.5 mM reduced glutathione (Merck, Cat No. 1040900005) 
at 37 °C for 24 h34,45. The samples from the FAE reactions were desalted using Amicon Ultra-0.5 centrifugal 
filter units (MWCO 30 kDa, Millipore, Cat No. UFC503024). Exchanged IgG4 were used to test competition 
with unmodified IgG1-131 or 637 in antigenic modulation experiments with TE671 cells. Exchanged (mono-
valent) IgG4 samples contained a 99 fold excess molar concentration of AChR-binding antibody (measured by 
radio-immunoprecipitation) compared to unmodified (cross-linking) AChR antibodies. Relevant controls in the 
form of normal human IgG4 and only Fab arm-exchanged IgG4 were included.
Cell surface fetal AChR functional assay. Patch clamp experiments were performed on HEK293 cells 
transiently transfected with fetal AChR subunits and EGFP using PEI, with cells at ~70% confluence one day after 
plating in six well tissue culture dishes. Briefly, cDNA encoding the human muscle AChR α, β, δ, and γ-subunits 
were cloned into the mammalian expression vector pcDNA3.1 (Invitrogen). These were co-transfected with 
pEGFP-N1 (Invitrogen), which contains cDNA encoding EGFP. After 5–7 h of exposure to a mix of 3 μg cDNA, 
20% glucose and PEI in 2 mL of culture medium, the cells were plated onto poly-L-lysine-coated coverslips, and 
patch-clamped between two and three days later.
All experiments were performed at room temperature using the whole-cell patch clamp configuration. 
Recording pipettes were made of thin-walled borosilicate glass (GC150TF-10, Harvard Apparatus). Pipette tips 
were fire-polished to a final resistance of 2–4 MΩ (MF-900 Microforge, Narishige). Extracellular solutions con-
tained (in mM): NaCl 150, KCl 2.8, HEPES 10, MgCl2 2, CaCl2 2 and glucose 10 with pH adjusted to 7.4 using 
NaOH. Pipette solutions contained (in mM): NaCl 4, KCl 144, HEPES 10, MgCl2 2, ATP 2 and EGTA 10 with pH 
adjusted to 7.2 using KOH. All measurements were performed at a holding potential of −60mV. Currents were 
amplified using an Axopatch-1D amplifier (Molecular Devices) and, after filtering at 5 kHz, sampled to hard disk 
at 25 kHz. Data analysis was performed with pClamp 10.5 (Molecular Devices).
Fast solution exchange was accomplished using the modified HSSE-2/3 application system (ALA Scientific 
Instruments). A four-barrel perfusion pipette with a tip diameter of around 300 μm was used to switch between 
control and test solutions, both of which consisted of an agonist containing solution for receptor stimulation 
(extracellular solution with 1 mM acetylcholine) and an agonist-free solution for agonist removal (extracellular 
solution). In contrast to the control solution, the test solution additionally contained 5 μg/mL purified IgG1-131 
in both the agonist containing and the agonist-free solution.
Statistical analysis. Statistical analysis was done using Prism software version 5.00 (GraphPad). Binding 
of IgG1-131 and IgG1-637 to fetal and adult AChR extracts and RMS cell modulation was analyzed by a two way 
ANOVA with Bonferroni posttest. Data from IgG-131/IgG-637 competition, the AChR blocking RIA and anti-
genic modulation of Fab arm-exchanged samples were analyzed by one-way ANOVA and Bonferroni multiple 
comparison test. AChR currents in individual cells were analyzed by t-test, while repetitive AChR current meas-
urements were analyzed by regression analysis. P values equal to or less than 0.05 were considered as significant.
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